TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Blackmon SH, Correa AM, Skoracki R, Chevray PM, Kim MP, Mehran RJ, Rice DC , Roth JA, Swisher SG, Vaporciyan AA, Yu P, Walsh GL, Hofstetter WL
A systematic review and meta-analysis performed in 2011 on 13,800 cancer patients and 23,340 healthy controls reported that adherence to the MedDiet was related to a reduced risk of death from cancer and specifically that the regular consumption of olive oil may reduce the probability of cancer (65)
G.CrinerG
